Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Jonathan Kaufman

Concepts (280)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Intensive Care Units, Pediatric
7
2020
293
1.550
Why?
Cardiac Surgical Procedures
11
2020
608
1.530
Why?
Heart Defects, Congenital
11
2020
920
1.270
Why?
Multiple Myeloma
8
2024
310
1.050
Why?
Hyponatremia
2
2016
42
0.860
Why?
Antineoplastic Combined Chemotherapy Protocols
13
2024
1996
0.800
Why?
Quality Improvement
3
2018
1325
0.780
Why?
Postoperative Complications
9
2020
2962
0.770
Why?
Enteral Nutrition
7
2020
212
0.680
Why?
Airway Extubation
1
2020
60
0.580
Why?
Infant, Newborn
23
2020
6449
0.560
Why?
Intensive Care Units
5
2020
923
0.550
Why?
Cardiac Care Facilities
1
2017
11
0.530
Why?
Vascular Access Devices
1
2018
30
0.530
Why?
Dexamethasone
9
2024
368
0.520
Why?
Heart Diseases
3
2016
341
0.500
Why?
Postoperative Care
3
2014
292
0.500
Why?
Hypernatremia
1
2016
7
0.500
Why?
Hypoplastic Left Heart Syndrome
2
2014
119
0.460
Why?
Vasodilator Agents
3
2013
326
0.460
Why?
Stem Cell Transplantation
2
2022
189
0.450
Why?
Boronic Acids
3
2014
37
0.430
Why?
Tachycardia
2
2014
58
0.420
Why?
Unnecessary Procedures
1
2014
54
0.410
Why?
Blood Chemical Analysis
1
2014
109
0.410
Why?
Parenteral Nutrition
1
2015
102
0.410
Why?
Infant
18
2020
10093
0.400
Why?
Pyrazines
3
2014
94
0.400
Why?
Infant, Premature
3
2020
622
0.390
Why?
Milrinone
1
2013
26
0.390
Why?
Calcitonin
1
2013
26
0.390
Why?
Norwood Procedures
1
2013
33
0.390
Why?
Cardiovascular Surgical Procedures
1
2013
30
0.390
Why?
Prilocaine
1
2013
5
0.380
Why?
Methemoglobinemia
1
2013
13
0.380
Why?
Lidocaine
1
2013
55
0.370
Why?
Protein Precursors
1
2013
127
0.370
Why?
Antibodies, Monoclonal
5
2025
1511
0.360
Why?
Tidal Volume
1
2013
108
0.360
Why?
Nutritional Status
1
2015
344
0.360
Why?
Bronchiolitis
1
2013
87
0.360
Why?
Masks
1
2013
70
0.360
Why?
Anesthetics, Local
1
2013
106
0.350
Why?
Thrombosis
2
2018
397
0.350
Why?
Continuous Positive Airway Pressure
1
2013
91
0.350
Why?
Cardiac Output, Low
1
2012
53
0.350
Why?
Critical Illness
2
2016
905
0.350
Why?
Cardiotonic Agents
1
2012
94
0.350
Why?
Catheter Obstruction
1
2011
4
0.340
Why?
Weight Gain
1
2015
561
0.330
Why?
C-Reactive Protein
1
2013
427
0.330
Why?
Chylothorax
1
2010
20
0.320
Why?
Octreotide
1
2010
23
0.320
Why?
Length of Stay
6
2018
1342
0.310
Why?
Heart Rate
1
2013
844
0.300
Why?
Heparin
1
2011
246
0.300
Why?
Abnormalities, Multiple
1
2011
193
0.290
Why?
Bortezomib
7
2024
54
0.290
Why?
Catheterization, Central Venous
1
2011
120
0.290
Why?
Thoracic Surgical Procedures
1
2010
95
0.290
Why?
Gastrostomy
2
2020
123
0.290
Why?
Antibodies, Monoclonal, Murine-Derived
5
2013
96
0.280
Why?
Retrospective Studies
17
2020
17291
0.280
Why?
Seizures
1
2013
489
0.280
Why?
Humans
49
2025
145625
0.270
Why?
Vasculitis
1
2008
69
0.270
Why?
Extracorporeal Membrane Oxygenation
2
2012
369
0.270
Why?
Lymphoma, Non-Hodgkin
3
2015
124
0.270
Why?
Male
36
2025
73014
0.260
Why?
Sepsis
1
2013
668
0.240
Why?
Colorado
5
2020
4588
0.240
Why?
Antibodies, Monoclonal, Humanized
3
2025
992
0.240
Why?
Palliative Care
1
2015
1032
0.240
Why?
Female
34
2025
79080
0.230
Why?
Receptor, ErbB-3
1
2025
48
0.230
Why?
Neuregulin-1
1
2025
49
0.220
Why?
Critical Care
1
2011
700
0.210
Why?
Respiration, Artificial
3
2020
711
0.210
Why?
Prospective Studies
8
2025
8087
0.200
Why?
Incidence
5
2020
2910
0.200
Why?
Enterocolitis, Necrotizing
2
2018
39
0.200
Why?
Rhabdomyosarcoma
1
2024
65
0.200
Why?
Biomarkers
3
2016
4329
0.200
Why?
Intubation, Gastrointestinal
2
2020
76
0.190
Why?
Follow-Up Studies
7
2020
5397
0.190
Why?
Intubation, Intratracheal
2
2020
328
0.190
Why?
Child, Preschool
12
2019
11888
0.180
Why?
Maintenance Chemotherapy
1
2022
41
0.180
Why?
Child
12
2024
22638
0.180
Why?
Cohort Studies
5
2019
6045
0.180
Why?
Time Factors
8
2017
7079
0.170
Why?
Acute Kidney Injury
4
2020
861
0.170
Why?
Disease-Free Survival
5
2022
777
0.170
Why?
Cyclophosphamide
5
2020
275
0.170
Why?
Rituximab
6
2015
208
0.170
Why?
Drug Administration Schedule
6
2014
782
0.170
Why?
Cyanosis
1
2020
17
0.160
Why?
Immunoglobulin Light-chain Amyloidosis
1
2020
10
0.160
Why?
Risk Factors
8
2020
10840
0.160
Why?
Analysis of Variance
2
2013
1293
0.160
Why?
Fundoplication
1
2020
49
0.160
Why?
Smoldering Multiple Myeloma
1
2019
9
0.150
Why?
Calcaneus
1
2019
32
0.150
Why?
Clinical Trials as Topic
1
2024
1062
0.140
Why?
Ketorolac
1
2018
33
0.140
Why?
Treatment Outcome
10
2020
11744
0.140
Why?
Platelet Aggregation
1
2018
99
0.140
Why?
Lymphoma, B-Cell
2
2012
149
0.130
Why?
Gastroesophageal Reflux
1
2020
232
0.130
Why?
Urine Specimen Collection
1
2017
2
0.130
Why?
Catheters, Indwelling
1
2018
94
0.130
Why?
Combined Modality Therapy
2
2010
1269
0.130
Why?
Morphine
1
2018
169
0.120
Why?
Dose-Response Relationship, Drug
4
2014
2018
0.120
Why?
Diuretics
1
2016
66
0.120
Why?
Spectroscopy, Near-Infrared
1
2016
70
0.110
Why?
Sodium
1
2016
196
0.110
Why?
Bone Density
1
2019
492
0.110
Why?
Lymphoma, Follicular
2
2015
57
0.110
Why?
Aged
12
2025
26251
0.110
Why?
Logistic Models
4
2014
2112
0.110
Why?
Prognosis
5
2018
4331
0.110
Why?
Urinary Tract Infections
1
2017
207
0.110
Why?
Thalidomide
2
2015
43
0.110
Why?
Gestational Age
2
2020
989
0.100
Why?
Transplantation, Autologous
3
2022
303
0.100
Why?
Quality of Life
2
2024
3187
0.100
Why?
Hypertension, Pulmonary
1
2005
1957
0.100
Why?
Heart
1
2018
624
0.100
Why?
Remission Induction
2
2014
308
0.100
Why?
Calcitonin Gene-Related Peptide
1
2013
39
0.100
Why?
Port-Wine Stain
1
2013
4
0.100
Why?
Liver Function Tests
1
2013
103
0.100
Why?
Delivery Rooms
1
2013
11
0.090
Why?
Adult
13
2025
40821
0.090
Why?
Pediatrics
2
2011
1122
0.090
Why?
Administration, Topical
1
2013
153
0.090
Why?
Equipment Failure
1
2013
111
0.090
Why?
Health Care Surveys
2
2011
538
0.090
Why?
Middle Aged
12
2025
36359
0.090
Why?
Statistics, Nonparametric
1
2013
423
0.090
Why?
Intubation
1
2012
7
0.090
Why?
Lung
1
2005
4119
0.090
Why?
Respiration
1
2013
207
0.090
Why?
Pentobarbital
1
2011
17
0.090
Why?
Australia
1
2013
291
0.090
Why?
Survival Rate
2
2013
2078
0.090
Why?
Vein of Galen Malformations
1
2011
2
0.080
Why?
Patient Admission
1
2013
216
0.080
Why?
Hematopoietic Stem Cell Mobilization
1
2011
28
0.080
Why?
Airway Obstruction
1
2013
152
0.080
Why?
Down Syndrome
1
2018
529
0.080
Why?
Heterocyclic Compounds
1
2011
23
0.080
Why?
Peripheral Blood Stem Cell Transplantation
1
2011
35
0.080
Why?
Professional Practice
1
2011
58
0.080
Why?
Respiratory Function Tests
1
2013
543
0.080
Why?
Linear Models
1
2013
847
0.080
Why?
Status Epilepticus
1
2011
71
0.080
Why?
Receptors, CXCR4
1
2011
90
0.080
Why?
Intracranial Arteriovenous Malformations
1
2011
53
0.080
Why?
Chemoprevention
1
2011
91
0.080
Why?
Nutritional Support
1
2010
39
0.080
Why?
Ventilator Weaning
1
2010
38
0.080
Why?
Diet, Fat-Restricted
1
2010
79
0.080
Why?
Anesthetics, Intravenous
1
2010
67
0.080
Why?
Fatal Outcome
1
2011
302
0.080
Why?
Aortic Coarctation
1
2011
76
0.080
Why?
Electrocardiography
1
2013
666
0.080
Why?
ROC Curve
1
2012
613
0.080
Why?
Salvage Therapy
1
2011
163
0.080
Why?
Kinetics
1
2013
1553
0.080
Why?
Neoplasms
1
2025
2944
0.080
Why?
Infusions, Intravenous
3
2018
429
0.080
Why?
Propofol
1
2010
86
0.080
Why?
Birth Weight
1
2013
521
0.070
Why?
Molecular Targeted Therapy
1
2013
446
0.070
Why?
Drainage
1
2010
187
0.070
Why?
Maximum Tolerated Dose
3
2015
216
0.070
Why?
Hypnotics and Sedatives
1
2011
221
0.070
Why?
Analgesics, Opioid
1
2018
1158
0.070
Why?
Device Removal
1
2010
149
0.070
Why?
Lymphoma
1
2011
251
0.070
Why?
Plasmapheresis
1
2008
24
0.070
Why?
Alprostadil
1
2008
29
0.070
Why?
High-Frequency Ventilation
1
2008
44
0.070
Why?
Diagnosis, Differential
1
2013
1500
0.070
Why?
Vincristine
3
2015
148
0.070
Why?
Kidney
1
2016
1491
0.070
Why?
Renal Replacement Therapy
1
2008
102
0.070
Why?
Neoplasm Recurrence, Local
1
2014
1156
0.060
Why?
Kaplan-Meier Estimate
3
2015
959
0.060
Why?
Neoadjuvant Therapy
1
2010
474
0.060
Why?
Adolescent
8
2018
22451
0.060
Why?
Predictive Value of Tests
1
2012
2097
0.060
Why?
Immunologic Factors
1
2008
244
0.060
Why?
Doxorubicin
3
2015
414
0.060
Why?
Patient Readmission
1
2012
771
0.060
Why?
Interleukin-6
1
2010
782
0.060
Why?
Interferons
1
2007
186
0.060
Why?
Preoperative Care
1
2008
375
0.060
Why?
Anticoagulants
1
2011
743
0.060
Why?
Adrenal Cortex Hormones
1
2008
483
0.060
Why?
Aged, 80 and over
3
2025
8351
0.060
Why?
rho-Associated Kinases
1
2005
77
0.060
Why?
Immunosuppressive Agents
1
2008
824
0.050
Why?
HIV Infections
1
2019
3210
0.050
Why?
Antineoplastic Agents
2
2022
2218
0.050
Why?
Hemorrhage
1
2008
824
0.050
Why?
Intracellular Signaling Peptides and Proteins
1
2005
456
0.050
Why?
Prednisone
2
2015
229
0.050
Why?
Attitude of Health Personnel
1
2011
1212
0.050
Why?
Autografts
1
2022
56
0.050
Why?
Boron Compounds
1
2022
28
0.050
Why?
Melphalan
1
2022
43
0.050
Why?
Thrombocytopenia
2
2015
205
0.040
Why?
Pneumonia
2
2020
633
0.040
Why?
Lung Diseases
1
2008
787
0.040
Why?
Glycine
1
2022
184
0.040
Why?
Case-Control Studies
2
2019
3633
0.040
Why?
Recurrence
2
2015
1125
0.040
Why?
Severity of Illness Index
1
2008
2910
0.040
Why?
Viscera
1
2020
17
0.040
Why?
Immunoglobulin Light Chains
1
2020
52
0.040
Why?
Immunoglobulin Heavy Chains
1
2020
83
0.040
Why?
Cellulitis
1
2020
55
0.040
Why?
Nervous System
1
2020
68
0.040
Why?
Heart Failure
1
2012
2323
0.030
Why?
South Africa
1
2019
262
0.030
Why?
Cardiopulmonary Bypass
1
2020
217
0.030
Why?
Postoperative Period
1
2018
344
0.030
Why?
Thrombelastography
1
2018
181
0.030
Why?
Anti-Retroviral Agents
1
2019
250
0.030
Why?
Rats
1
2005
5574
0.030
Why?
Infant Mortality
1
2018
127
0.030
Why?
Specimen Handling
1
2017
178
0.030
Why?
Comorbidity
1
2020
1652
0.030
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2018
344
0.030
Why?
Ultrasonography
1
2019
788
0.030
Why?
Disease Progression
1
2022
2857
0.030
Why?
Peripheral Nervous System Diseases
1
2015
133
0.030
Why?
Hydroxamic Acids
1
2014
95
0.030
Why?
Oligopeptides
1
2015
264
0.020
Why?
Hyperbilirubinemia
1
2013
11
0.020
Why?
Gastrointestinal Diseases
1
2015
220
0.020
Why?
Pulmonary Embolism
1
2015
245
0.020
Why?
Liver Failure
1
2013
75
0.020
Why?
Neutropenia
1
2013
153
0.020
Why?
Chemical Fractionation
1
2011
29
0.020
Why?
Administration, Oral
1
2014
867
0.020
Why?
Neural Conduction
1
2012
92
0.020
Why?
Cytarabine
1
2011
66
0.020
Why?
Longitudinal Studies
1
2019
3005
0.020
Why?
Multiple Organ Failure
1
2012
122
0.020
Why?
Neurologic Examination
1
2011
129
0.020
Why?
Ventricular Function, Right
1
2014
300
0.020
Why?
Benzylamines
1
2011
44
0.020
Why?
Prostaglandins
1
2011
94
0.020
Why?
Survival Analysis
1
2014
1372
0.020
Why?
Antigens, CD34
1
2011
89
0.020
Why?
Mouth
1
2011
84
0.020
Why?
Blood Component Removal
1
2011
26
0.020
Why?
Granulocyte Colony-Stimulating Factor
1
2011
90
0.020
Why?
Liver Cirrhosis
1
2013
276
0.020
Why?
Internationality
1
2011
156
0.020
Why?
Risk Assessment
1
2020
3678
0.020
Why?
Indoles
1
2014
509
0.020
Why?
Double-Blind Method
1
2014
2064
0.020
Why?
Electroencephalography
1
2011
570
0.020
Why?
Cost-Benefit Analysis
1
2011
632
0.020
Why?
Hematopoietic Stem Cells
1
2011
432
0.020
Why?
Animals
2
2010
38030
0.020
Why?
Hospital Mortality
1
2012
1037
0.020
Why?
Internet
1
2011
656
0.020
Why?
Young Adult
2
2011
14240
0.010
Why?
Liver
1
2013
1859
0.010
Why?
Immunotherapy
1
2007
669
0.010
Why?
Randomized Controlled Trials as Topic
1
2007
1754
0.010
Why?
Mice, Inbred C57BL
1
2010
6021
0.010
Why?
United States
1
2011
16041
0.010
Why?
Mice
1
2010
18266
0.010
Why?
Kaufman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)